Details for Patent: 10,662,160

Which drugs does patent 10,662,160 protect, and when does it expire?

Patent 10,662,160 protects ORLADEYO and is included in one NDA.

This patent has twenty patent family members in twenty countries.

Summary for Patent: 10,662,160

Title:	Crystalline salts of a plasma kallikrein inhibitor
Abstract:	Disclosed are crystalline salts of Compound I, methods of preparing them, and related pharmaceutical preparations thereof. Also disclosed are methods of treatment using the crystalline salts of the invention. ##STR00001##
Inventor(s):	El-Kattan; Yahya (Vestavia Hills, AL), Babu; Yarlagadda S. (Birmingham, AL)
Assignee:	BioCryst Pharmaceuticals, Inc. (Durham, NC)
Application Number:	16/671,649
Patent Claim Types: see list of patent claims	Use; Composition; Compound; Dosage form;

Drugs Protected by US Patent 10,662,160

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Biocryst	ORLADEYO	berotralstat hydrochloride	CAPSULE;ORAL	214094-001	Dec 3, 2020		RX	Yes	No				Y		PROPHYLAXIS TO PREVENT ATTACKS OF HEREDITARY ANGIOEDEMA (HAE) IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
Biocryst	ORLADEYO	berotralstat hydrochloride	CAPSULE;ORAL	214094-002	Dec 3, 2020		RX	Yes	Yes				Y		PROPHYLAXIS TO PREVENT ATTACKS OF HEREDITARY ANGIOEDEMA (HAE) IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER

International Family Members for US Patent 10,662,160

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	116951
Australia	2019374115
Brazil	112021008249